Q32 Bio

OverviewSuggest Edit

Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. The company has a product pipeline including a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R), and a complement therapeutics platform that generates fusion proteins intended to downregulate complement activity specifically in disease-affected tissues.
TypePrivate
HQCambridge, MA, US
Websiteq32bio.com

Latest Updates

Employees (est.) (Nov 2021)27(+4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Q32 Bio

Shelia Violette

Shelia Violette

Founder, Chief Scientific Officer and President of Research
Michael Broxson

Michael Broxson

Chief Executive Officer
Charles Romano

Charles Romano

Vice President of Clinical Development Operations
Show more

Q32 Bio Office Locations

Q32 Bio has an office in Cambridge
Cambridge, MA, US (HQ)
1 Main St floor 7
Show all (1)

Q32 Bio Financials and Metrics

Summary Metrics

Q32 Bio total Funding

$106 m

Q32 Bio latest funding size

$60 m

Time since last funding

a year ago

Q32 Bio investors

Q32 Bio's latest funding round in October 2020 was reported to be $60 m. In total, Q32 Bio has raised $106 m
Show all financial metrics

Q32 Bio Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Q32 Bio Online and Social Media Presence

Embed Graph

Q32 Bio News and Updates

Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors

CAMBRIDGE, Mass., Aug. 3, 2021 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Kathy LaPorte to its Board of Directors. Ms. LaPorte, who brings over 30 years of experience in...

Q32 Bio Appoints Experienced Biopharmaceutical Leader Mark Iwicki as Chairman of Board of Directors

CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of industry leader Mark Iwicki as Chairman of its Board of Directors. Mr. Iwicki will succeed Dr. David Grayzel as...

Q32 Bio Raises $46M in Series A Funding

Q32 Bio, a Cambridge, Massachusetts-based biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases, raised $46m in Series A funding. The round was led by Atlas Venture with participation from OrbiMed Advisors, Abingworth, Sanofi Ventures, University o…

Q32 Bio Frequently Asked Questions

  • Who are Q32 Bio key executives?

    Q32 Bio's key executives are Shelia Violette, Michael Broxson and Charles Romano.

  • How many employees does Q32 Bio have?

    Q32 Bio has 27 employees.

  • Who are Q32 Bio competitors?

    Competitors of Q32 Bio include Morphic Therapeutic, Vedanta Biosciences and MOMA Therapeutics.

  • Where is Q32 Bio headquarters?

    Q32 Bio headquarters is located at 1 Main St floor 7, Cambridge.

  • Where are Q32 Bio offices?

    Q32 Bio has an office in Cambridge.

  • How many offices does Q32 Bio have?

    Q32 Bio has 1 office.